Three-year disease-free survival rate was similar in ER+/HER2+ and in ER+/HER2- carcinomas (70% vs. 73%) and was as low in ER-/HER2+ tumors as in ER-/HER2- tumors (61% and 63%) [31]. The gene discussed is ERBB2; the disease is carcinoma.